Open company graph database — free web & API
Login

New Japan Science Inc.

株式会社新日本科学SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (SNBL)Alias
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
3,001
Related companies
13
§01

Basic information

BASIC
Head office
28th Floor, St. Luke Tower, 8-1 Akashi-cho, Chuo-ku, TokyoSources
Chief executive
Ryooichi NagataSources
Capital
9,679,070,000  (96 100 million)
Employees (non-consolidated)
1,436 people
Employees (consolidated)
3,001 people
Start date
1973-05-01
End date
§02

Websites

2 DOMAINS
§03

Business

3
Contracted pharmaceutical development (CRO) businessSourcesTranslational Research (TR) businessSourcesMedipolis businessSources
§04

Related companies

13 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Gemseki Corporation
Group
Medipolis Energy Co., Ltd. Sources
Group Subsidiary
New Japan Science Inari Research Center Co., Ltd.
Group
Veritas Academy Educational Corporation Sources
Group Subsidiary
Clinical Study Support Inc. Sources
Group Subsidiary
Shin Nihon Kagaku Tasso Co., Ltd. Sources
Group Subsidiary
Satsuma Pharmaceuticals, Inc. Sources
Group Subsidiary
SNLD Corporation Sources
Group Subsidiary
Satsuma
Group Subsidiary
Fureai Support Co., Ltd. Sources
Group Subsidiary
メディポリス国際陽子線治療センター
Group
New Japan Science PPD Co., Ltd. Sources
Group Subsidiary
Shin Nihon General Construction Co., Ltd. Sources
Group Subsidiary
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

65 EVENTS

Founded the South Japan Dog Center (with an animal hospital) in Kagoshima CitySources

1957: Founded the South Japan Dog Center (with an animal hospital) in Kagoshima City: Building imagesSources

Started contracted safety testing (preclinical trials) as Japan’s first contracted pharmaceutical development research institutionSources

1960: Started contract work for safety testing (preclinical trials) as Japan's first contract research organization for pharmaceutical developmentSources

Changed the company name to New Japan Science Co., Ltd.Sources

1974: Changed company name to Shin Nihon Kagaku Co., Ltd.Sources

Established a safety research institute in Yoshida Town, Kagoshima District (now Miyanoura Town, Kagoshima City) and relocated the headquartersSources

1980: Established a safety research institute in Yoshida Town, Kagoshima District (now Miyanoura Town, Kagoshima City) and relocated the headquartersSources

Successfully built the world’s first online computer system in preparation for GLP implementationSources

Successful construction of the world’s first online computer system in preparation for GLP (Good Laboratory Practice) "Standards for Conducting Nonclinical Safety Studies of Pharmaceuticals"Sources

1982: Prepared for the implementation of GLP (Good Laboratory Practice) "Standards for the conduct of nonclinical trials on drug safety" by successfully building the world's first online computer systemSources

Obtained GLP compliance from the Ministry of Health, Labour and Welfare and began safety testing; expanded the research buildingSources

Obtained GLP compliance (first in Japan as a CRO) from the Ministry of Health, Labour and Welfare, started safety testing, and expanded the research buildingSources

1983: Obtained GLP compliance (first in Japan as a CRO) from the Ministry of Health, Labour and Welfare, started safety testing, and expanded the research wingSources

Built an experimental NHP breeding facility in IndonesiaSources

1986: Built an experimental NHP breeding facility in IndonesiaSources

Established a U.S. branch in MarylandSources

Established U.S. branch office in Maryland as a sales baseSources

1988: Established a U.S. branch office in Maryland as a sales base in the United StatesSources

Started experimental NHP breeding in China in collaboration with a local companySources

Started experimental NHP breeding in China in collaboration with local companiesSources

1989: Started experimental NHP breeding in China in collaboration with a local companySources

Divested the U.S. branch as SNBL U.S.A., Ltd. and built a clinical pharmacology testing medical institution (CPC Clinic) in Kagoshima CitySources

Divided U.S. branch into SNBL U.S.A., Ltd. and built a clinical pharmacology testing facility (CPC Clinic) in Kagoshima CitySources

1991: Divested the U.S. branch as SNBL U.S.A., Ltd.; built a clinical pharmacology testing medical facility (CPC Clinic) in Kagoshima CitySources

Started contracted clinical pharmacology and Phase I clinical trial businessSources

1993: Began contract work for clinical pharmacology and Phase I clinical trialsSources

Established a new Translational Research (TR) divisionSources

1997: Established a Translational Research (TR) divisionSources

Established a drug metabolism analysis center in Kainan City, Wakayama Prefecture, and began analysis and pharmacokinetic testing servicesSources

1998: Established a drug metabolism analysis center in Kainan City, Wakayama Prefecture; started analysis and pharmacokinetic testing servicesSources

Started contracted Phase II and Phase III clinical trials, relocated SNBL U.S.A., Ltd. to Everett, a suburb of Seattle, and established a nonclinical testing facilitySources

Started contract clinical Phase II and III trials, relocated SNBL U.S.A., Ltd. to Everett, Washington, and established a new nonclinical testing facilitySources

1999: Started contract work for Phase II and Phase III clinical trials: Moved SNBL U.S.A., Ltd. to Everett, a suburb of Seattle, and established a nonclinical testing facility: Building imagesSources

SNBL U.S.A., Ltd. obtained AAALAC International accreditationSources

SNBL U.S.A., Ltd. obtained AAALAC International certificationSources

2000: SNBL U.S.A., Ltd. obtained AAALAC International accreditationSources

Built an experimental NHP breeding facility in Guangdong Province, ChinaSources

2003: Built an experimental NHP breeding facility in Guangdong Province, ChinaSources

Listed on the Tokyo Stock Exchange Mothers market and built a clinical pharmacology testing medical institution on the campus of the University of Maryland in Baltimore, USASources

Listed on Tokyo Mothers Market and built a clinical pharmacology testing facility on the campus of the University of Maryland in BaltimoreSources

2004: Listed on the Tokyo Stock Exchange Mothers market; built a clinical pharmacology testing medical facility on the campus of the University of Maryland in Baltimore, USASources

Start of Medipolis businessSources

2005: Started the Medipolis businessSources

Construction of experimental NHP breeding facility in CambodiaSources

2007: Construction of an experimental NHP breeding facility in CambodiaSources

Market change to First Section of Tokyo Stock ExchangeSources

2008: Market change to First Section of the Tokyo Stock ExchangeSources

Safety Research Institute obtains AAALAC International certificationSources

Safety Research Institute obtained AAALAC International certificationSources

2011: Safety Research Institute: Obtained AAALAC International accreditationSources

Wave Life Sciences, a nucleic acid pharmaceutical developer, goes public on NASDAQ and establishes joint venture New Japan Science PPD Co., Ltd.Sources

Wave Life Sciences, a nucleic acid pharmaceutical developer (established 2012), goes public on NASDAQ and establishes joint venture New Japan Science PPD Co., Ltd.Sources

2015: Wave Life Sciences, a nucleic acid pharmaceutical developer (established by us in 2012), listed on the U.S. NASDAQ market: Established joint venture New Japan Science PPD Co., Ltd.Sources

Satsuma Pharmaceuticals (established 2016) goes public on NASDAQSources

Satsuma Pharmaceuticals goes public on NASDAQSources

2019: Satsuma Pharmaceuticals, established by us in 2016, listed on the U.S. NASDAQ marketSources

Transition to Prime Market of new market segment on Tokyo Stock Exchange and consolidation of Inari Research Co., Ltd. as a subsidiarySources

Transition to the Prime Market of the New Market Division at the Tokyo Stock Exchange, consolidating Inar Research Co., Ltd. as a subsidiarySources

2022: Transition to the Prime Market of the new market segment of the Tokyo Stock Exchange: Consolidated Inari Research Co., Ltd. as a subsidiarySources

Consolidation of Satsuma Pharmaceuticals as a subsidiarySources

2023: Consolidated Satsuma Pharmaceuticals as a subsidiarySources

New research building established at Kagoshima headquartersSources

New headquarters building and research wing established in KagoshimaSources

2024: New research building at the Kagoshima headquarters: Building imageSources

§07

News

3 ARTICLES

Release of the First Half Financial Summary VideoSources

We released the "3-Minute Overview of the First Half Financial Summary for FY 2027 Q3" narrated by President Hirama's AI voice. The video can be viewed via the link provided.

Kagoshima Science and Technology Consortium Partnership Agreement CeremonySources

On July 21, 2026, a ceremony to conclude the KSTC partnership agreement was held at Kagoshima Prefectural Office. Kagoshima's universities, high schools, companies, and the Prefectural Board of Education collaborated to enhance inquiry activities and science and mathematics education. Shinnihon Science also expressed its intention to contribute to the development of future science talents in the region.

Groundbreaking Ceremony for New EU Laboratory Building at Kagoshima HeadquartersSources

Shin Nihon Scientific Co., Ltd. held a groundbreaking ceremony for the expansion of the EU laboratory and main building elevator tower at its Kagoshima headquarters, aiming for completion in fall 2027.

§09

Sources & updates

SOURCES
↑